DB04907ExperimentalGene Therapies
Sitimagene ceradenovec is a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour, given in addition to standard surgery and... It is being developed by Ark Therapeutics.
- Mechanism
- Curator reviewed
EG009 works by delivering a gene into the healthy brain cells remaining after the tumour has been removed. These then produce an enzyme that kills the cells trying to divide, preventing a recurrence of a tumour.
- Primary indication
- Intended for the treatment of brain cancer.Curator reviewed
- Code names
- EG009
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of October 01, 2026
Which companies are running trials of Sitimagene ceradenovec, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account